Back to top
more

Inotek Pharmaceuticals Corporation (ITEK)

(Real Time Quote from BATS)

$3.04 USD

3.04
NA

-0.16 (-5.00%)

Updated Jan 4, 2018 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

Rocket Pharmaceuticals, Inc. [ITEK]

Reports for Purchase

Showing records 1 - 17 ( 17 total )

Company: Rocket Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 1

10/06/2017

Company Report

Pages: 3

We are terminating coverage due to the departure from the firm of the covering analyst

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Company: Rocket Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 2

07/11/2017

Company Report

Pages: 5

Final Strikeout in Glaucoma Leaves Inotek Looking for New Players; Downgrading to Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: DAVIS C

Price: 10.00

Research Provided by a Third Party

Company: Rocket Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 3

05/24/2017

Daily Note

Pages: 3

Corrected - Coverage Update - Healthcare

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Rocket Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 4

05/24/2017

Company Report

Pages: 4

We are dropping coverage of ITEK shares to reallocate our research resources

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Rocket Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 5

05/24/2017

Daily Note

Pages: 3

Coverage Update - Healthcare

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Rocket Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 6

05/12/2017

Company Report

Pages: 7

FDC Data Nearly Ready; Monotherapy Is on Back-Burner

Provider: H.C. Wainwright & Co., Inc.

Analyst: DAVIS C

Price: 25.00

Research Provided by a Third Party

Company: Rocket Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 7

04/12/2017

Daily Note

Pages: 3

Completed Enrollment in FDC Clarifies Key Event Timeline

Provider: H.C. Wainwright & Co., Inc.

Analyst: DAVIS C

Price: 10.00

Research Provided by a Third Party

Company: Rocket Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 8

03/17/2017

Company Report

Pages: 4

Inotek All-In on FDC Phase 2 Data Expected Mid-2017

Provider: H.C. Wainwright & Co., Inc.

Analyst: DAVIS C

Price: 10.00

Research Provided by a Third Party

Company: Rocket Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 9

01/04/2017

Company Report

Pages: 5

Such a Trabecular Mesh; Lowering Target to $7

Provider: H.C. Wainwright & Co., Inc.

Analyst: DAVIS C

Price: 10.00

Research Provided by a Third Party

Company: Rocket Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 10

01/03/2017

Company Report

Pages: 4

Phase 3 MATrX-3 Fails

Provider: Roth Capital Partners, Inc.

Analyst: YANIV S

Price: 10.00

Research Provided by a Third Party

Company: Rocket Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 11

01/03/2017

Company Report

Pages: 5

MATrX-1 Disappoints; Nevertheless, We Remain Optimistic on Trabo''s Future

Provider: Roth Capital Partners, Inc.

Analyst: YANIV S

Price: 10.00

Research Provided by a Third Party

Company: Rocket Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 12

12/22/2016

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Rocket Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 13

12/21/2016

Company Report

Pages: 11

MATrX-1 Should be an Easy Lay-Up

Provider: Roth Capital Partners, Inc.

Analyst: YANIV S

Price: 25.00

Research Provided by a Third Party

Company: Rocket Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 14

12/01/2016

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Rocket Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 15

11/30/2016

Company Report

Pages: 17

Giving Red Eye a Black Eye: Initiating with Buy and $10 PT

Provider: Roth Capital Partners, Inc.

Analyst: YANIV S

Price: 50.00

Research Provided by a Third Party

Company: Rocket Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 16

11/11/2016

Company Report

Pages: 4

ITEK Our Favorite Small Cap Pick Into Year-End

Provider: H.C. Wainwright & Co., Inc.

Analyst: DAVIS C

Price: 10.00

Research Provided by a Third Party

Company: Rocket Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 17

09/20/2016

Company Report

Pages: 28

We are initiating with a Buy and $22 target.

Provider: H.C. Wainwright & Co., Inc.

Price: 75.00

Research Provided by a Third Party
// eof